Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pulse Biosciences, Inc.NASDAQ: PLSE
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $4.97M fell 4.2% year over year, ahead of the -15.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 160.1% from the prior quarter. Over 3 fiscal years it compounded at +60.5% a year.
Context
- Stock-based compensation amounted to 6130.6% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.2% holds above the trailing-twelve-month pace of -15.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 21.46M USD
- Year-over-year change
- +57.9%
- 4-year CAGR
- +10.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.46M | +57.9% |
| FY2024 | 2024-12-31 | 13.59M | +89.2% |
| FY2023 | 2023-12-31 | 7.18M | +38.3% |
| FY2022 | 2022-12-31 | 5.19M | -64.4% |
| FY2021 | 2021-12-31 | 14.6M | — |
Stock-Based Compensation vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.4% is the 6th highest of 11, against a peer median of -9.6%.
- Stock-based compensation amounts to 1474.4% of revenue for PLSE, versus a peer median of 18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $118.47M USD | -23.8% | — | 17.6% | |
| LTM Jan 2026 | $45.65M USD | +1845.1% | — | 54.5% | |
| LTM Jun 2026 | $34.27M USD | +82.5% | +146.7% | 1800.0% | |
| LTM Apr 2026 | $29.4M USD | +9.3% | +14.5% | 10.1% | |
| LTM Mar 2026 | $18.99M USD | +142.5% | +39.0% | 17.2% | |
| LTM Jun 2026 | $17.47M USD | -15.4% | +60.5% | 1474.4% | |
| LTM Jun 2026 | $16.18M USD | -17.0% | — | 361.7% | |
| LTM Jun 2026 | $11.99M USD | -31.8% | -39.6% | 22.0% | |
| LTM Mar 2026 | $10.83M USD | -2.2% | -16.7% | 1.9% | |
| LTM Mar 2026 | $7.95M USD | -35.1% | -8.6% | 3.6% | |
| LTM Mar 2026 | €7.38M EUR | -44.8% | — | 19.8% | |
| Peer median (excluding PLSE) | — | -9.6% | +3.0% | 18.7% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.6M | 5.19M | 7.18M | 13.59M | 21.46M |
| Change in Working Capital | (6.2M) | (3.72M) | 768K | 2.47M | (5.02M) |
| Accounts Receivables | (61K) | 20K | 109K | 48K | (274K) |
| Inventory | (5.82M) | (2.65M) | 0 | 0 | (136K) |
| Accounts Payables | 1.16M | (1.3M) | 263K | (201K) | 1.13M |
| Other Working Capital | (1.47M) | 221K | 396K | 2.63M | (5.74M) |
| Other Non-Cash Items | 13K | 8.66M | 13K | 6K | 1.15M |
| Operating Cash Flow | (54.1M) | (47.01M) | (33.04M) | (36.34M) | (54.12M) |
| Capital Expenditures | (437K) | (401K) | (121K) | (125K) | (315K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (20K) |
| Investing Cash Flow | 7.56M | (401K) | (121K) | (125K) | (335K) |
| Debt Repayment | 407K | 65M | 0 | 0 | 0 |
| Common Stock Issued | 56.7M | 14.86M | 16.39M | 59.65M | 17.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.51M | 75K | (6K) | 50.49M | 0 |
| Financing Cash Flow | 62.69M | 79.94M | 16.39M | 110.14M | 17.15M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.15M | 32.53M | (16.77M) | 73.67M | (37.3M) |
| Free Cash Flow | (54.53M) | (47.41M) | (33.16M) | (36.47M) | (54.44M) |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.